查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813452

2032 年減重藥物研究市場預測：按平台、藥物、技術、應用、最終用戶和地區進行的全球分析

Microgravity Drug Research Market Forecasts to 2032 - Global Analysis By Platform, Drug, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球減重力藥物研究市場預計在 2025 年達到 8.165 億美元，到 2032 年將達到 20.684 億美元，預測期內的複合年成長率為 14.2%。

減重藥物研究探索在類似國際太空站的低重力環境下進行藥物開發。這種獨特的環境會改變細胞行為、蛋白質結晶和分子相互作用，從而更精確地研究生物機制。促進更高品質蛋白質晶體的生長並增強3D組織建模可以加速藥物發現並改善製劑策略。透過消除地球引力的干擾，減重使得研究原本難以重現的複雜生物醫學現象成為可能。

根據《藥物研究中的現代統計應用》，在臨床研究中，生物統計學控制研究設計、樣本大小估計、隨機化和結果分析，以可靠地識別治療效果，同時最大限度地降低風險。

增加投資、太空商業化和優質蛋白質結晶

低重力環境使得高度有序的蛋白質晶體得以形成，這在地球上難以實現，從而改善藥物標靶識別和分子表徵。這些進步正在加速生技藥品和精準療法的發展。包括國際太空站（ISS）在內的低地球軌道平台的商業化為藥物研發開闢了新的途徑。此外，航太機構與生技公司之間的合作正在培育可擴展的治療方法研發研究模式。

高成本和物流

在太空進行實驗需要專門的有效載荷整合、發射協調和任務後分析，所有這些都會導致高昂的營運成本。此外，有限的軌道平台使用權和較長的實驗前置作業時間阻礙了快速原型製作和可擴展性。太空臨床試驗的監管合規性增加了一層複雜性，使得小型生物技術公司難以參與。除非實施成本削減策略和精簡物流，否則這些挑戰可能會減緩其廣泛應用。

新治療方法的開發

研究人員正在探索再生醫學、腫瘤學、神經退化性疾病以及其他細胞行為與地球顯著不同的疾病的太空模型。這已推動幹細胞分化、組織工程和藥物療效測試取得突破性進展。模擬失重環境下疾病進展的能力有助於設計更有針對性、更有效的治療方法。隨著太空研究的普及，製藥公司可望利用這些洞見，打造具有更佳臨床療效的下一代治療方法。

與先進地面技術的競爭

雖然失重研究具有明顯的優勢，但它面臨著來自器官晶片系統、人工智慧藥物研發平台和高解析度成像技術等尖端地面技術的日益激烈的競爭。此外，模擬模型和實驗室自動化的不斷改進正在縮小太空和地面研究成果之間的差距。除非失重平台能夠在治療產量和成本效益方面展現出明顯的優勢，否則其市場相關性可能會受到質疑。

COVID-19的影響：

由於旅行限制和供應鏈中斷，新冠疫情導致太空任務暫時停止，多個低重力研究計劃也因此延後。然而，這場危機也凸顯了去中心化且富有韌性的研發生態系統的重要性。隨著製藥公司尋求創新方法加速藥物研發，人們對太空平台的興趣也急劇上升。疫情也促使航太機構與生技公司之間建立了新的夥伴關係，並著重於低重力環境下的抗病毒研究和免疫反應研究。

預計國際太空站(ISS) 部門將成為預測期內最大的部門。

國際太空站(ISS) 預計將在預測期內佔據最大的市場佔有率，這得益於其完善的基礎設施和在生物醫學實驗方面取得的驕人成績。作為最便捷的軌道實驗室，ISS 支持廣泛的藥物研究，包括蛋白質結晶、幹細胞行為和組織再生。其模組化設計和持續的人員駐留使其能夠進行即時監控和迭代測試。

預計再生醫學領域在預測期內將以最高的複合年成長率成長。

再生醫學領域預計將在預測期內呈現最高成長率，這得益於太空中觀察到的獨特細胞反應。低重力環境促進幹細胞增生、分化和組織形成，為開發器官衰竭、肌肉骨骼疾病和創傷治療的治療方法提供了前所未有的機會。研究人員正在利用軌道平台研究無支架組織形成和細胞外基質動力學，這些過程在地球上難以複製。

比最大的地區

北美憑藉其強大的太空基礎設施、強大的政府支持以及蓬勃發展的生物技術生態系統，預計將在預測期內佔據最大的市場佔有率。該地區擁有NASA和SpaceX等主要企業，以及許多活躍於軌道生命科學領域的學術機構。有利的法律規範和諸如「減重生物醫學研究計畫」之類的資助計畫正在加速技術創新。此外，先進的製藥生產能力和創業投資興趣也鞏固了北美在這一新興領域的主導地位。

複合年成長率最高的地區：

在預測期內，由於對太空探勘和生物醫學研究的投資不斷增加，預計亞太地區將呈現最高的複合年成長率。中國、日本和印度等國家正在擴展其軌道能力，並推出專門的生命科學任務。政府主導的促進太空商業化和國際合作的舉措，為低重力環境下的藥物研究創造了肥沃的土壤。該地區製藥業的成長以及對先進療法日益成長的需求，進一步推動了市場的成長。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球減重力藥物研究市場（按平台）

  • 國際太空站（ISS）
  • 跳樓機
  • 商業太空站
  • 基於立方體衛星的實驗
  • 拋物線飛行
  • 地面設施
  • 彈道火箭
  • 高空氣球
  • 月球和火星模擬任務
  • 其他平台

6. 全球低重力藥物研究市場（按藥物）

  • 小分子藥物
  • 再生醫學
  • 生物製藥
  • 酵素療法
  • 疫苗

7. 全球減重力藥物研究市場（按技術）

  • 分子對接與模擬
  • 3D細胞培養和類器官
  • 基因組和轉錄組分析
  • 蛋白質結晶
  • 基於人工智慧的藥物發現
  • 其他技術

8. 全球減重力藥物研究市場（按應用）

  • 材料科學
  • 太空探勘
  • 燃燒科學
  • 藥物開發與研究
  • 動態
  • 生物技術
  • 其他用途

9. 全球低重力藥物研究市場（按最終用戶）

  • 政府機構
  • 商業航太公司
  • 製藥公司
  • 研究機構
  • 其他最終用戶

10. 全球低重力藥物研究市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • NASA
  • European Space Agency（ESA）
  • SpacePharma
  • Emulate Bio
  • Zymeworks
  • Axiom Space
  • BioServe Space Technologie
  • Blue Origin
  • SpaceX
  • BenchSci
  • Varda Space Industries
  • CytoReason
  • Deep Genomics
  • Insilico Medicine
  • Nanoracks
  • Redwire Space
  • StemRad
  • Orbit Fab
Product Code: SMRC30901

According to Stratistics MRC, the Global Microgravity Drug Research Market is accounted for $816.5 million in 2025 and is expected to reach $2,068.4 million by 2032 growing at a CAGR of 14.2% during the forecast period. Microgravity drug research explores pharmaceutical development in low-gravity environments, such as aboard the International Space Station. This unique setting alters cellular behavior, protein crystallization, and molecular interactions, enabling more precise studies of biological mechanisms. It facilitates the growth of higher-quality protein crystals and enhances 3D tissue modeling, which can accelerate drug discovery and improve formulation strategies. By removing Earth's gravitational interference, microgravity allows researchers to investigate complex biomedical phenomena that are otherwise difficult to replicate.

According to Statistical Applications in Modern Pharmaceutical Research In clinical research, biostatistics governs study design, sample size estimation, randomization, and outcome analysis, ensuring that therapeutic benefits are identified while minimizing risks.

Market Dynamics:

Driver:

Increased investment, commercialization of space & superior protein crystallization

Microgravity conditions enable the formation of highly ordered protein crystals, which are difficult to achieve on Earth, thereby improving drug target identification and molecular characterization. These advancements are accelerating the development of biologics and precision therapies. The commercialization of low Earth orbit platforms, including the International Space Station (ISS), has opened new avenues for pharmaceutical R&D. Additionally, collaborations between space agencies and biotech firms are fostering scalable research models for therapeutic discovery.

Restraint:

High costs and logistics

Conducting experiments in space requires specialized payload integration, launch coordination, and post-mission analysis, all of which contribute to high operational expenses. Moreover, limited access to orbital platforms and long lead times for experiment cycles hinder rapid prototyping and scalability. Regulatory compliance for space-based trials adds another layer of complexity, making it difficult for smaller biotech firms to participate. These challenges may slow down widespread adoption unless cost-reduction strategies and streamlined logistics are implemented.

Opportunity:

Development of new therapeutic modalities

Researchers are exploring space-based models for regenerative medicine, oncology, and neurodegenerative diseases, where cellular behavior differs significantly from terrestrial conditions. This has led to breakthroughs in stem cell differentiation, tissue engineering, and drug efficacy testing. The ability to simulate disease progression in microgravity is enabling the design of more targeted and effective treatments. As space research becomes more accessible, pharmaceutical companies are expected to leverage these findings to create next-generation therapies with enhanced clinical outcomes.

Threat:

Competition from advanced terrestrial technologies

While microgravity research presents distinct advantages, it faces growing competition from cutting-edge terrestrial technologies such as organ-on-chip systems, AI-driven drug discovery platforms, and high-resolution imaging techniques. Additionally, continuous improvements in simulation models and lab automation are narrowing the gap between space-based and ground-based research outcomes. If microgravity platforms fail to demonstrate clear superiority in therapeutic yield or cost-effectiveness, their market relevance may be challenged.

Covid-19 Impact:

The COVID-19 pandemic temporarily disrupted space missions and delayed several microgravity research projects due to travel restrictions and supply chain interruptions. However, the crisis also underscored the importance of decentralized and resilient R&D ecosystems. As pharmaceutical companies sought innovative ways to accelerate drug discovery, interest in space-based platforms surged. The pandemic catalyzed new partnerships between space agencies and biotech firms, focusing on antiviral research and immune response studies in microgravity.

The international space station (ISS) segment is expected to be the largest during the forecast period

The international space station (ISS) segment is expected to account for the largest market share during the forecast period due to its established infrastructure and proven track record in biomedical experimentation. As the most accessible orbital laboratory, the ISS supports a wide range of pharmaceutical studies, including protein crystallization, stem cell behavior, and tissue regeneration. Its modular design and continuous human presence allow for real-time monitoring and iterative testing.

The regenerative medicines segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the regenerative medicines segment is predicted to witness the highest growth rate driven by the unique cellular responses observed in space. Microgravity conditions enhance stem cell proliferation, differentiation, and tissue formation, offering unprecedented opportunities for developing therapies for organ failure, musculoskeletal disorders, and wound healing. Researchers are leveraging orbital platforms to study scaffold-free tissue assembly and extracellular matrix dynamics, which are difficult to replicate on Earth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share attributed to robust space infrastructure, strong government backing, and a thriving biotech ecosystem. The region hosts key players such as NASA, SpaceX, and numerous academic institutions actively engaged in orbital life sciences. Favorable regulatory frameworks and funding programs like the Biomedical Research in Microgravity initiative are accelerating innovation. Additionally, the presence of advanced pharmaceutical manufacturing capabilities and venture capital interest is reinforcing North America's dominance in this emerging field.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR fueled by increasing investments in space exploration and biomedical research. Countries like China, Japan, and India are expanding their orbital capabilities and launching dedicated life sciences missions. Government-led initiatives promoting space commercialization and international collaborations are creating fertile ground for microgravity drug research. The region's growing pharmaceutical sector and rising demand for advanced therapies are further propelling market growth.

Key players in the market

Some of the key players in Microgravity Drug Research Market include NASA, European Space Agency (ESA), SpacePharma, Emulate Bio, Zymeworks, Axiom Space, BioServe Space Technologies, Blue Origin, SpaceX, BenchSci, Varda Space Industries, CytoReason, Deep Genomics, Insilico Medicine, Nanoracks, Redwire Space, StemRad, and Orbit Fab.

Key Developments:

In August 2025, ESA issued press releases for 2025 programme milestones and mid-year programme/Flight Ticket Initiative updates. ESA's 2025 release slate covers launch timetables, programme partnerships and IAC participation notices.

In March 2024, Blue Origin announced New Glenn national-security launch contract wins and continued New Shepard crewed flights through mid-2025 (NS-32 / NS-33 / NS-35 etc.). The 2025 items highlight contract awards and routine suborbital flight cadence for New Shepard.

In May 2025, Deep Genomics announced an expansion of its AI foundation model platform (REPRESS) to improve prediction of RNA biology and accelerate RNA therapeutic design. The release describes platform advances for decoding gene regulation and supporting therapeutic discovery workflows.

Platforms Covered:

  • International Space Station (ISS)
  • Drop Towers
  • Commercial Space Stations
  • CubeSat-based Experiments
  • Parabolic Flights
  • Ground-based Facilities
  • Suborbital Rockets
  • High-Altitude Balloons
  • Lunar and Martian Analog Missions
  • Other Platforms

Drugs Covered:

  • Small Molecule Drugs
  • Regenerative Medicines
  • Biologics
  • Enzyme Therapies
  • Vaccines

Technologies Covered:

  • Molecular Docking & Simulation
  • 3D Cell Culture & Organoids
  • Genomic & Transcriptomic Profiling
  • Protein Crystallization
  • AI-Based Drug Discovery
  • Other Technologies

Applications Covered:

  • Material Science
  • Space Exploration
  • Combustion Science
  • Drug Development & Pharmaceutical Research
  • Fluid Dynamics
  • Biotechnology
  • Other Applications

End Users Covered:

  • Government Agencies
  • Commercial Space Companies
  • Pharmaceutical Companies
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Microgravity Drug Research Market, By Platform

  • 5.1 Introduction
  • 5.2 International Space Station (ISS)
  • 5.3 Drop Towers
  • 5.4 Commercial Space Stations
  • 5.5 CubeSat-based Experiments
  • 5.6 Parabolic Flights
  • 5.7 Ground-based Facilities
  • 5.8 Suborbital Rockets
  • 5.9 High-Altitude Balloons
  • 5.10 Lunar and Martian Analog Missions
  • 5.11 Other Platforms

6 Global Microgravity Drug Research Market, By Drug

  • 6.1 Introduction
  • 6.2 Small Molecule Drugs
  • 6.3 Regenerative Medicines
  • 6.4 Biologics
  • 6.5 Enzyme Therapies
  • 6.6 Vaccines

7 Global Microgravity Drug Research Market, By Technology

  • 7.1 Introduction
  • 7.2 Molecular Docking & Simulation
  • 7.3 3D Cell Culture & Organoids
  • 7.4 Genomic & Transcriptomic Profiling
  • 7.5 Protein Crystallization
  • 7.6 AI-Based Drug Discovery
  • 7.7 Other Technologies

8 Global Microgravity Drug Research Market, By Application

  • 8.1 Introduction
  • 8.2 Material Science
  • 8.3 Space Exploration
  • 8.4 Combustion Science
  • 8.5 Drug Development & Pharmaceutical Research
  • 8.6 Fluid Dynamics
  • 8.7 Biotechnology
  • 8.8 Other Applications

9 Global Microgravity Drug Research Market, By End User

  • 9.1 Introduction
  • 9.2 Government Agencies
  • 9.3 Commercial Space Companies
  • 9.4 Pharmaceutical Companies
  • 9.5 Research Institutions
  • 9.6 Other End Users

10 Global Microgravity Drug Research Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 NASA
  • 12.2 European Space Agency (ESA)
  • 12.3 SpacePharma
  • 12.4 Emulate Bio
  • 12.5 Zymeworks
  • 12.6 Axiom Space
  • 12.7 BioServe Space Technologie
  • 12.8 Blue Origin
  • 12.9 SpaceX
  • 12.10 BenchSci
  • 12.11 Varda Space Industries
  • 12.12 CytoReason
  • 12.13 Deep Genomics
  • 12.14 Insilico Medicine
  • 12.15 Nanoracks
  • 12.16 Redwire Space
  • 12.17 StemRad
  • 12.18 Orbit Fab

List of Tables

  • Table 1 Global Microgravity Drug Research Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Microgravity Drug Research Market Outlook, By Platform (2024-2032) ($MN)
  • Table 3 Global Microgravity Drug Research Market Outlook, By International Space Station (ISS) (2024-2032) ($MN)
  • Table 4 Global Microgravity Drug Research Market Outlook, By Drop Towers (2024-2032) ($MN)
  • Table 5 Global Microgravity Drug Research Market Outlook, By Commercial Space Stations (2024-2032) ($MN)
  • Table 6 Global Microgravity Drug Research Market Outlook, By CubeSat-based Experiments (2024-2032) ($MN)
  • Table 7 Global Microgravity Drug Research Market Outlook, By Parabolic Flights (2024-2032) ($MN)
  • Table 8 Global Microgravity Drug Research Market Outlook, By Ground-based Facilities (2024-2032) ($MN)
  • Table 9 Global Microgravity Drug Research Market Outlook, By Suborbital Rockets (2024-2032) ($MN)
  • Table 10 Global Microgravity Drug Research Market Outlook, By High-Altitude Balloons (2024-2032) ($MN)
  • Table 11 Global Microgravity Drug Research Market Outlook, By Lunar and Martian Analog Missions (2024-2032) ($MN)
  • Table 12 Global Microgravity Drug Research Market Outlook, By Other Platforms (2024-2032) ($MN)
  • Table 13 Global Microgravity Drug Research Market Outlook, By Drug (2024-2032) ($MN)
  • Table 14 Global Microgravity Drug Research Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 15 Global Microgravity Drug Research Market Outlook, By Regenerative Medicines (2024-2032) ($MN)
  • Table 16 Global Microgravity Drug Research Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 17 Global Microgravity Drug Research Market Outlook, By Enzyme Therapies (2024-2032) ($MN)
  • Table 18 Global Microgravity Drug Research Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 19 Global Microgravity Drug Research Market Outlook, By Technology (2024-2032) ($MN)
  • Table 20 Global Microgravity Drug Research Market Outlook, By Molecular Docking & Simulation (2024-2032) ($MN)
  • Table 21 Global Microgravity Drug Research Market Outlook, By 3D Cell Culture & Organoids (2024-2032) ($MN)
  • Table 22 Global Microgravity Drug Research Market Outlook, By Genomic & Transcriptomic Profiling (2024-2032) ($MN)
  • Table 23 Global Microgravity Drug Research Market Outlook, By Protein Crystallization (2024-2032) ($MN)
  • Table 24 Global Microgravity Drug Research Market Outlook, By AI-Based Drug Discovery (2024-2032) ($MN)
  • Table 25 Global Microgravity Drug Research Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 26 Global Microgravity Drug Research Market Outlook, By Application (2024-2032) ($MN)
  • Table 27 Global Microgravity Drug Research Market Outlook, By Material Science (2024-2032) ($MN)
  • Table 28 Global Microgravity Drug Research Market Outlook, By Space Exploration (2024-2032) ($MN)
  • Table 29 Global Microgravity Drug Research Market Outlook, By Combustion Science (2024-2032) ($MN)
  • Table 30 Global Microgravity Drug Research Market Outlook, By Drug Development & Pharmaceutical Research (2024-2032) ($MN)
  • Table 31 Global Microgravity Drug Research Market Outlook, By Fluid Dynamics (2024-2032) ($MN)
  • Table 32 Global Microgravity Drug Research Market Outlook, By Biotechnology (2024-2032) ($MN)
  • Table 33 Global Microgravity Drug Research Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 34 Global Microgravity Drug Research Market Outlook, By End User (2024-2032) ($MN)
  • Table 35 Global Microgravity Drug Research Market Outlook, By Government Agencies (2024-2032) ($MN)
  • Table 36 Global Microgravity Drug Research Market Outlook, By Commercial Space Companies (2024-2032) ($MN)
  • Table 37 Global Microgravity Drug Research Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 38 Global Microgravity Drug Research Market Outlook, By Research Institutions (2024-2032) ($MN)
  • Table 39 Global Microgravity Drug Research Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.